Accelerating cancer research through AI-powered epidemiology tools.
We believe that every researcher deserves access to world-class epidemiology tools. Our platform democratizes cancer research by automating complex statistical analyses and manuscript generation.
Founded in 2024 by a team of oncologists, epidemiologists, and AI researchers, we've helped hundreds of scientists publish in top-tier journals including The Lancet, Lancet Oncology, and Lancet Global Health.
Our vision: By 2030, every cancer epidemiology study published in major journals will use AI-assisted analysis tools.
Professor of Epidemiology at Peking University Cancer Hospital. 20+ years in cancer epidemiology research with 150+ publications in Lancet family journals.
Harvard T.H. Chan School of Public Health. Expert in biostatistics and survival analysis. Former WHO consultant on cancer surveillance.
PhD in Computational Biology from MIT. Specializes in applying large language models to scientific writing and peer review.
Former data scientist at IARC/WHO. Expert in GLOBOCAN data integration and cancer registry harmonization.
Three researchers from Peking University, Harvard, and MIT came together with a vision to democratize cancer epidemiology research.
First version of the platform released with GLOBOCAN integration and basic statistical analysis capabilities.
Our platform helped produce its first Lancet publication - a global lung cancer trends analysis covering 185 countries.
Added full integration with NCI's SEER program, enabling US-focused cancer survival analysis.
Launched AI-powered Lancet manuscript generation with STROBE compliance checking.
Reached 500+ active researchers across 12 countries with 47 published papers.
Every analysis follows best practices recommended by top journals. We never compromise on statistical integrity.
Cancer knows no borders. Our platform covers 185 countries and 36 cancer types to support worldwide research.
We believe in transparency. Our methods are documented, our code is open-source, and our data sources are cited.
Continuously pushing the boundaries of what's possible with AI-assisted epidemiological research.
Empowering the next generation of researchers with accessible tools and comprehensive training resources.
Ultimately, our work serves patients. Better research leads to better prevention, detection, and treatment.
Help us accelerate cancer research and save lives.